2. Search Result
Search Result
Pathways Recommended: PI3K/Akt/mTOR
Results for "

K(ATP)

" in MedChemExpress (MCE) Product Catalog:

71

Inhibitors & Agonists

3

Fluorescent Dye

1

Peptides

8

Natural
Products

10

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-A0176
    Glisoxepide

    		Potassium Channel Cardiovascular Disease Metabolic Disease
    Glisoxepide, a sulphonamide derivative, is an orally available nonselective K(ATP) channel blocker, with antihyperglycemic activity and cardiovascular regulation effect .
    Glisoxepide
  • HY-14256
    BMS-191095
    1 Publications Verification

    		 Potassium Channel Cardiovascular Disease Neurological Disease
    BMS-191095 is a selective activator of mitochondrial ATP-sensitive potassium (mitoKATP) channels. BMS-191095 inhibits human platelet aggregation by opening mitochondrial K(ATP) channels .
    BMS-191095
  • HY-108573
    P-1075
    1 Publications Verification

    		 Potassium Channel Cardiovascular Disease
    P-1075 is a potent activator of sulfonylurea receptor 2-associated ATP-sensitive potassium channels (SUR2-KIR6), with an EC50 value of 45 nM for SUR2B-KIR6 channel activation . P-1075 also P1075 opens mitochondrial K(ATP) channels and generates reactive oxygen species resulting in cardioprotection of rabbit hearts .
    P-1075
  • HY-100276
    Naminidil

    BMS 234303-01

    		 Potassium Channel Cardiovascular Disease
    Naminidil is a cyanoguanidine KATP opener.
    Naminidil
  • HY-14255
    Levcromakalim
    4 Publications Verification

    (-)-Cromakalim; BRL 38227

    		 Potassium Channel Cardiovascular Disease
    Levcromakalim ((-)-Cromakalim) is an ATP-sensitive K + channel (KATP) activator.
    Levcromakalim
  • HY-12184
    ONO-AE 248

    		Others Cardiovascular Disease
    ONO-AE 248 is a selective EP3 receptor agonist with cardioprotective activity. ONO-AE 248 reduces myocardial infarction size by selectively binding to the EP3α receptor in mice. The cardioprotective effect of ONO-AE 248 is independent of hemodynamic effects. The mechanism of ONO-AE 248 may involve activation of protein kinase C and opening of K(ATP) channels .
    ONO-AE 248
  • HY-126704
    Tedisamil

    KC-8857

    		 Potassium Channel Cardiovascular Disease
    Tedisamil (KC-8857) is an antiarrhythmic compound with important biological activities. Tedisamil exhibits a significant slowing effect on heart rate, which is achieved by inhibiting the transient outward potassium current (I(to)) in the atrium. Tedisamil inhibits multiple potassium currents, including IK, K(ATP), and PKA-activated chloride channels, thereby prolonging the cardiac action potential and QT interval, and increasing cardiac reentry. Tedisamil has antiarrhythmic effects on ventricular arrhythmias and atrial flutter in animal models .
    Tedisamil
  • HY-155941
    5-Hydroxydecanoic acid

    		Potassium Channel Neurological Disease
    5-Hydroxydecanoic acid (5-HD） is a KATP channel antagonist，which has the effect of blocking the K KATP channel only during ischaemia by competing with the ATP binding site and does not affect pancreatic KATP channels .
    5-Hydroxydecanoic acid
  • HY-N11690
    Oleandrigenin

    		Na+/K+ ATPase Cardiovascular Disease Cancer
    Oleandrigenin is a potent cardiotonic steroid. Oleandrigenin shows Na +/K +-ATP-ase inhibiting and cytotoxic activities .
    Oleandrigenin
  • HY-U00173
    U89232

    		Potassium Channel Cardiovascular Disease
    U-89232 appears to be a cardioselective KATP channel opener.
    U89232
  • HY-121183
    Aprikalim

    RP 52891

    		 Potassium Channel Cardiovascular Disease
    Aprikalim (RP 52891), a potassium channel opener (KCO), activates ATP-sensitive K+ (KATP) channels in guinea pig ventricular myocytes. Using patch-clamp techniques, it was found that aprikalim enhances KATP channel activity more effectively in Mg-NDP solution compared to standard solutions. In Mg-NDP solution, aprikalim reduced the sensitivity of KATP channels to ATP, increasing the concentration of ATP required to inhibit channel activity by half (K1) from 56 μM to 180 μM. However, this effect diminished over time. Aprikalim's ability to activate KATP channels in Mg-NDP solution suggests potential therapeutic implications in modulating cardiac excitability and may relate to changes in channel protein enzymatic activity under experimental conditions .
    Aprikalim
  • HY-120158
    ZD0947

    		Potassium Channel Neurological Disease
    ZD0947 is an ATP-sensitive potassium channel activator with relatively effective activation of smooth muscle KATP channels (SUR2B/Kir6.1 and SUR2B/Kir6.2). ZD0947 partially antagonizes pancreatic KATP channels (SUR1/Kir6.2) and cardiac KATP channels (SUR2A/Kir6.2). ZD0947 is potentially used to inhibit overactive bladder (OAB) .
    ZD0947
  • HY-B0682
    Mitiglinide

    KAD-1229 free acid anhydrous; S21403 free acid anhydrous

    		 Potassium Channel Metabolic Disease
    Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K + (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes .
    Mitiglinide
  • HY-17451
    Glibornuride

    		Potassium Channel Metabolic Disease
    Glibornuride is a blocker of ATP-sensitive K + channels (KATP channel) with a pKi of 5.75 . Antidiabetic agent .
    Glibornuride
  • HY-15208
    Clamikalant sodium

    HMR 1098

    		 Potassium Channel Neurological Disease
    Clamikalant sodium (HMR 1098) is an ATP-sensitive potassium (KATP) channel blocker. Clamikalant sodium can be used for the research of arrhythmia .
    Clamikalant sodium
  • HY-17398
    Mitiglinide calcium

    KAD-1229 anhydrous; S21403 anhydrous

    		 Potassium Channel Metabolic Disease
    Mitiglinide Calcium (KAD-1229 anhydrous), an insulinotropic agent, is an ATP-sensitive K + (KATP) channel antagonist. Mitiglinide Calcium is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium can be used for the research of type 2 diabetes .
    Mitiglinide calcium
  • HY-B0682A
    Mitiglinide calcium hydrate

    KAD-1229; S-21403

    		 Potassium Channel Metabolic Disease
    Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K + (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .
    Mitiglinide calcium hydrate
  • HY-128933
    AMP-PNP tetralithium
    1 Publications Verification

    Adenylyl-imidodiphosphate tetralithium

    		 Potassium Channel Metabolic Disease
    AMP-PNP tetralithium (Adenylyl-imidodiphosphate tetralithium) is a non-hydrolysable analogue of ATP and inhibits KATP channels .
    AMP-PNP tetralithium
  • HY-169249
    Aekatperone

    Z1620764636

    		 Potassium Channel Metabolic Disease
    Aekatperone is a reversible KATP channel inhibitor, with an IC50 of 9 μM. Aekatperone can be used for the research of congenital hyperinsulinism (CHI) .
    Aekatperone
  • HY-B0682S2
    Mitiglinide-d5 calcium

    		Potassium Channel Metabolic Disease
    Mitiglinide-d5 (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes[1][2].
    Mitiglinide-d5 calcium
  • HY-B0682S1
    (2R)-Mitiglinide-d5 calcium

    		Potassium Channel Metabolic Disease
    (2R)-Mitiglinide-d5 (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes[1][2].
    (2R)-Mitiglinide-d5 calcium
  • HY-15206
    Glibenclamide
    Maximum Cited Publications
    19 Publications Verification

    Glyburide

    		 Potassium Channel Mitochondrial Metabolism Autophagy CFTR P-glycoprotein Metabolic Disease
    Glibenclamide (Glyburide) is an orally active ATP-sensitive K + channel (KATP) inhibitor and can be used for the research of diabetes and obesity . Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR) . Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability . Glibenclamide can induce autophagy .
    Glibenclamide
  • HY-B0682AR
    Mitiglinide calcium hydrate (Standard)

    		Potassium Channel Metabolic Disease
    Mitiglinide (calcium hydrate) (Standard) is the analytical standard of Mitiglinide (calcium hydrate). This product is intended for research and analytical applications. Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K + (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .
    Mitiglinide calcium hydrate (Standard)
  • HY-B0682S
    Mitiglinide-d8 calcium hydrate

    		Potassium Channel Metabolic Disease
    Mitiglinide-d8 (calcium hydrate) (KAD-1229-d8) is the deuterium labeled Mitiglinide calcium hydrate. Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes[1][2].
    Mitiglinide-d8 calcium hydrate
  • HY-101069
    Y-26763
    1 Publications Verification

    		 Potassium Channel Cardiovascular Disease
    Y-26763 is a K + channel opener and active metabolite of Y-27152 . Y-26763 is an ATP-sensitive K + (KATP) channel activator .
    Y-26763
  • HY-15206S
    Glyburide-d11

    		Isotope-Labeled Compounds Potassium Channel Mitochondrial Metabolism Autophagy CFTR P-glycoprotein Metabolic Disease
    Glyburide-d11 is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].
    Glyburide-d11
  • HY-15206S1
    Glyburide-d3

    Glyburide-d3

    		 Potassium Channel Mitochondrial Metabolism Autophagy CFTR P-glycoprotein Metabolic Disease
    Glyburide-d3 is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].
    Glyburide-d3
  • HY-15206R
    Glibenclamide (Standard)

    Glyburide (Standard)

    		 Mitochondrial Metabolism Autophagy CFTR P-glycoprotein Potassium Channel Metabolic Disease
    Glibenclamide (Standard) is the analytical standard of Glibenclamide. This product is intended for research and analytical applications. Glibenclamide (Glyburide) is an orally active ATP-sensitive K + channel (KATP) inhibitor and can be used for the research of diabetes and obesity . Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR) . Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability . Glibenclamide can induce autophagy .
    Glibenclamide (Standard)
  • HY-119306
    MCC-134

    		Potassium Channel Cardiovascular Disease
    MCC-134, a blocker of mitochondrial and opener of surface ATP-sensitive K+ (KATP) channels, abrogates cardioprotective effects of chronic hypoxia. MCC-134 is a vasorelaxing agent .
    MCC-134
  • HY-17451R
    Glibornuride (Standard)

    		Potassium Channel Metabolic Disease
    Glibornuride (Standard) is the analytical standard of Glibornuride. This product is intended for research and analytical applications. Glibornuride is a blocker of ATP-sensitive K+ channels (KATP channel) with a pKi of 5.75 . Antidiabetic agent .
    Glibornuride (Standard)
  • HY-119322
    Tifenazoxide

    NN414

    		 Potassium Channel Metabolic Disease
    Tifenazoxide (NN414) is a potent, orally active and SUR1/Kir6.2 selective K ATP channels opener. Tifenazoxide has antidiabetic effect, can inhibit glucose stimulated insulin release in vitro and in vivo, and has a beneficial effect on glucose homeostasis .
    Tifenazoxide
  • HY-B0401
    Tolbutamide
    3 Publications Verification

    		 Na+/K+ ATPase Metabolic Disease Cancer
    Tolbutamide is an orally active KATP inhibitor. Tolbutamide inhibits cell proliferation, stimulates exocytosis of glucagon and reduces fetal lethality of mice. Tolbutamide can be used in the research of diabete .
    Tolbutamide
  • HY-114690
    PNU-140975

    BVT.3531

    		 Potassium Channel Neurological Disease
    PNU-140975 (BVT.3531) is a novel and potent bioactive compound. PNU-140975 can reduce body weight and activates KATP channel in isolated arcuate neurons in rats .
    PNU-140975
  • HY-U00201
    KRN4884

    		Potassium Channel Cardiovascular Disease
    KRN4884 is a K + channel opener. In the presence of intracellular ATP (1 mM), KRN4884 (0.1-3 μM) activates KATP channels in a concentration-dependent manner (EC50=0.55 μM).
    KRN4884
  • HY-108582
    Y-27152

    		Potassium Channel Cardiovascular Disease
    Y-27152, a proagent of the KATP (Kir6) channel opener Y-26763, is a long-acting K+ channel opener with less tachycardia: antihypertensive effects in hypertensive rats and dogs in conscious state .
    Y-27152
  • HY-136615
    5-Hydroxydecanoate sodium

    		Potassium Channel Neurological Disease
    5-Hydroxydecanoate sodium is a selective ATP-sensitive K + (KATP) channel blocker (IC50 of ~30 μM). 5-Hydroxydecanoate sodium is a substrate for mitochondrial outer membrane acyl-CoA synthetase and has antioxidant activity .
    5-Hydroxydecanoate sodium
  • HY-117283
    rel-Aprikalim

    rel-RP 52891

    		 Others Others
    rel-Aprikalim (rel-RP 52891) is the relative configuration of Aprikalim (HY-121183). Aprikalim (RP 52891), a potassium channel opener (KCO), activates ATP-sensitive K + (KATP) channels in guinea pig ventricular myocytes .
    rel-Aprikalim
  • HY-19216
    KR-30450

    SKP 450

    		 Potassium Channel Cardiovascular Disease
    KR-30450 (SKP 450) is a potent K +ATP opener, and a potassium channel activator. KR-30450 exerts more potent cardioprotective effects than Lemakalim (HY-14255). KR-30450 significantly improves reperfusion cardiac function. KR-30450 significantly attenuates reperfusion contracture and lactate dehydrogenase release .
    KR-30450
  • HY-108069
    Iptakalim hydrochloride

    		Potassium Channel nAChR Neurological Disease
    Iptakalim hydrochloride, a lipophilic para-amino compound, is a novel ATP-sensitive potassium channel (KATP) opener, as well as an α4β2-containing nicotinic acetylcholine receptor (nAChR) antagonist .
    Iptakalim hydrochloride
  • HY-117255
    ZM260384

    		Potassium Channel Others
    ZM260384 is a KATP channel opener that accelerates metabolism and inhibits the decline of guinea pig isolated diaphragm function, thereby affecting muscle contraction. ZM260384 can be used to study muscle function under hypoxic conditions .
    ZM260384
  • HY-108575
    Chromanol 293B

    		Potassium Channel CFTR Cardiovascular Disease
    Chromanol 293B is a selective blocker of the slow delayed rectifier K + current (IKs) with IC50 of 1-10 μM and a weak inhibitor of KATP channel. Chromanol 293B also blocks the CFTR chloride current with an IC50 of 19 μM .
    Chromanol 293B
  • HY-B0112
    Minoxidil
    5+ Cited Publications

    U10858

    		 Potassium Channel Endogenous Metabolite Cardiovascular Disease Cancer
    Minoxidil (U10858) is an ATP-sensitive potassium (KATP) channel opener, a potent oral antihypertensive agent and a peripheral vasodilator that promotes vasodilation also affects hair growth. Minoxidil is also a potent inhibitor of soybean lipoxygenaseare with an IC50 of 20 μM .
    Minoxidil
  • HY-108589
    PNU 37883 hydrochloride

    PNU 37883A

    		 Potassium Channel Neurological Disease
    PNU 37883 hydrochloride (PNU 37883A) is a selective vascular ATP-sensitive potassium (Kir6, KATP) channels blocker. PNU 37883 hydrochloride has diuretic effects with specific binding in kidney and vascular smooth muscle rather than in brain or pancreatic beta cells .
    PNU 37883 hydrochloride
  • HY-N1504
    Loureirin B

    		PAI-1 Potassium Channel ERK JNK Metabolic Disease
    Loureirin B, a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of plasminogen activator inhibitor-1 (PAI-1), with an IC50 of 26.10?μM; Loureirin B also inhibits KATP, the phosphorylation of ERK and JNK, and has anti-diabetic activity.
    Loureirin B
  • HY-113147A
    L-Palmitoylcarnitine chloride
    1 Publications Verification

    		 Potassium Channel Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    L-Palmitoylcarnitine chloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine chloride inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .
    L-Palmitoylcarnitine chloride
  • HY-113147
    L-Palmitoylcarnitine
    1 Publications Verification

    		 Potassium Channel Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    L-Palmitoylcarnitine, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .
    L-Palmitoylcarnitine
  • HY-B0341
    Nicorandil

    SG-75

    		 Potassium Channel Cardiovascular Disease
    Nicorandil (SG-75) is a potent potassium channel activator and targets vascular nucleoside diphosphate-dependent K + channels and cardiac ATP-sensitive K + channels (KATP). Nicorandil is a nicotinamide ester with vasodilatory and cardioprotective effects and has the potential for angina and forischemic heart diseases .
    Nicorandil
  • HY-113147B
    L-Palmitoylcarnitine TFA
    1 Publications Verification

    		 Endogenous Metabolite Potassium Channel Cardiovascular Disease Metabolic Disease
    L-Palmitoylcarnitine TFA, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine TFA inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .
    L-Palmitoylcarnitine TFA
  • HY-B0401R
    Tolbutamide (Standard)

    		Na+/K+ ATPase Metabolic Disease Cancer
    Tolbutamide (Standard) is the analytical standard of Tolbutamide. This product is intended for research and analytical applications. Tolbutamide is an orally active KATP inhibitor. Tolbutamide inhibits cell proliferation, stimulates exocytosis of glucagon and reduces fetal lethality of mice. Tolbutamide can be used in the research of diabete .
    Tolbutamide (Standard)
  • HY-115014
    Cibenzoline succinate

    Cifenline succinate; Ro 22-7796 succinate

    		 Potassium Channel Cardiovascular Disease Metabolic Disease
    Cibenzoline succinate (Cifenline succinate) is the succinate form of Cibenzoline (HY-106577). Cibenzoline succinate is an inhibitor for ATP-sensitive potassium (KATP) channel by affecting the pore-forming Kir6.2 subunit with IC50 of 22.2 µM. Cibenzoline succinate affects insulin secretion and exhibits antiarrhythmic and antidiabetic activities .
    Cibenzoline succinate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: